2-(2,5-dimethoxyphenyl)-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole is a complex organic molecule with the following chemical formula:
**C23H20N2O4**
This molecule, often referred to by its shorter name, **the oxadiazole,** is a promising candidate for use in various research areas, including:
* **Organic Electronics:** The oxadiazole's structure, with its electron-rich and electron-deficient regions, makes it a potential material for use in organic light-emitting diodes (OLEDs). These devices are used in displays and lighting applications.
* **Photovoltaic Devices:** The oxadiazole's ability to absorb light and transfer energy makes it a potential candidate for use in organic solar cells.
* **Sensors and Bioimaging:** The oxadiazole's fluorescence properties, particularly its sensitivity to changes in its environment, make it a potential component in fluorescent sensors and bioimaging probes. These probes can be used to detect specific molecules or track biological processes.
**Importance for Research:**
The oxadiazole is important for research because it exhibits several properties that make it a versatile building block for the development of new and improved materials with applications in various fields. These properties include:
* **High Electron Mobility:** This makes the oxadiazole suitable for use in organic electronic devices, where efficient charge transport is crucial.
* **Fluorescence:** Its fluorescence allows it to be used in sensors and bioimaging applications, where it can signal the presence of specific molecules or events.
* **Photoluminescence:** This property makes it suitable for use in OLEDs, where it can convert electrical energy into light.
* **Synthesis and Modification:** The oxadiazole's structure can be modified to tune its properties, allowing researchers to tailor it for specific applications.
Overall, the oxadiazole's unique combination of properties makes it a highly valuable research target with potential applications in numerous fields, such as electronics, solar energy, and biomedicine.
ID Source | ID |
---|---|
PubMed CID | 652093 |
CHEMBL ID | 1509422 |
CHEBI ID | 123341 |
Synonym |
---|
ASN 03156996 |
2-(2,5-dimethoxy-phenyl)-5-(4'-methoxy-biphenyl-4-yl)-[1,3,4]oxadiazole |
MLS000033371 , |
smr000002060 |
CHEBI:123341 |
AKOS000731800 |
2-(2,5-dimethoxyphenyl)-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole |
HMS2405N12 |
CHEMBL1509422 |
Q27213050 |
Class | Description |
---|---|
biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, PAPAIN | Carica papaya (papaya) | Potency | 11.2202 | 0.3000 | 12.5348 | 31.6228 | AID2161 |
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 35.4813 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 5.5528 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 5.5528 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 4.4668 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 34.9134 | 0.0020 | 14.6779 | 39.8107 | AID1476; AID1478; AID2158 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 45.8577 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
ClpP | Bacillus subtilis | Potency | 15.8489 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 3.2643 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
Smad3 | Homo sapiens (human) | Potency | 3.5481 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.7308 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 5.0119 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 54.0000 | 0.4000 | 7.1344 | 54.0000 | AID1418 |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 54.0000 | 0.0005 | 2.7739 | 25.1700 | AID1418 |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 54.0000 | 0.0005 | 2.8919 | 25.1700 | AID1418 |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 54.0000 | 0.0005 | 2.7478 | 25.1700 | AID1418 |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 54.0000 | 0.0005 | 2.7802 | 25.1700 | AID1418 |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 54.0000 | 0.0005 | 3.3142 | 49.5000 | AID1418 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Trypsin | Sus scrofa (pig) | AC50 | 10.3800 | 3.3400 | 16.7050 | 77.2200 | AID488789 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |